You are here: Industry Insights > AstraZeneca

News List

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC pharmaceutical-business-review
August 11, 2020
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402) ...
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma pharmatimes
August 11, 2020
AstraZeneca has revealed positive results from a Phase IIIb trial of Fasenra (benralizumab) in severe eosinophilic asthma patients.
AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine expresspharma
August 07, 2020
As per the deal, AstraZeneca will deliver the first 100 million doses this year and 200 million doses by the end of 2021.
AstraZeneca signs first deal to supply Covid-19 vaccine in China pharmaceutical-technology
August 07, 2020
AstraZeneca partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
AstraZeneca to develop Redx’s drug for fibrotic diseases pharmaceutical-technology
August 06, 2020
AstraZeneca has entered into an agreement with UK-based biotechnology company Redx Pharma to license a porcupine inhibitor, RXC006, for fibrotic diseases.
AstraZeneca forges licensing agreement with Redx Pharma pharmatimes
August 05, 2020
AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006.
AstraZeneca, Daiichi Sankyo Announce Collaboration for New Antibody Drug Conjugate americanpharmaceuticalreview
August 04, 2020
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential ...
Emergent BioSolutions Signs Agreement with AstraZeneca contractpharma
August 04, 2020
Emergent BioSolutions Inc. has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
Daiichi Sankyo, AstraZeneca Enter New $6B Global ADC Alliance contractpharma
August 03, 2020
To jointly develop and commercialize DS-1062, a TROP2 directed DXd antibody drug conjugate in Phase I for non-small cell lung cancer and breast cancer.
AZ' Farxiga hits all goals in chronic kidney disease trial pharmatimes
July 29, 2020
AstraZeneca's Farxiga’s (dapagliflozin) has hit all primary and secondary endpoints in a late stage trial assessing its use in patients with chronic kidney disease (CKD).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page